

# Trial of Homocysteine Reduction In the prevention of Vascular Events and Dementia in the elderly

<b>Submission date</b> 12/09/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 12/09/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 05/01/2011	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr David J Stott

### Contact details

Academic Section of Geriatric Medicine  
3rd Floor Centre Block  
Glasgow Royal Infirmary  
Glasgow  
United Kingdom  
G4 0SF  
+44 (0)141 211 4976  
[d.j.stott@clinmed.gla.ac.uk](mailto:d.j.stott@clinmed.gla.ac.uk)

## Additional identifiers

### Protocol serial number

112/57

## Study information

Scientific Title

**Acronym**

THRIVED

**Study objectives**

1. What are the effects of vitamin combinations (comprising of folic acid plus B12, B6 and B2, each alone and in combination) on serum homocysteine (HCY) in elderly patients with vascular disease?
2. Is telephone follow-up of cognitive function and of disability practicable in this cohort of patients?

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Ischaemic vascular disease

**Interventions**

Patients will receive vitamin folic acid (2 mg) plus vitamin B12 (400 mg) or placebo, vitamin B6 (25 mg) or placebo, and B2 (25 mg), in a factorial 2 by 2 design.

**Intervention Type**

Supplement

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Folic acid, Vitamins B12, B6 and B2

**Primary outcome(s)**

1. Serum HCY, plasma von Willebrand factor, vitamin levels (red cell folate, serum vitamin B12, B2 and B6)
2. Piloting of telephone follow-up of cognition (Telephone Interview for Cognitive Status [TICS<sub>m</sub>]) and of disability (Barthel Index and short Instrumental Activities for Daily Living [ADL] scale)

**Key secondary outcome(s))**

Not provided at time of registration

**Completion date**

30/11/2003

## Eligibility

**Key inclusion criteria**

1. Age greater than 65 years
2. Ischaemic vascular disease (at least one of the following: history of angina pectoris, acute myocardial infarction, evidence of major ischaemia or previous infarction on 12-lead electrocardiogram, ischaemic stroke, transient ischaemic attack, intermittent claudication, previous surgery for ischaemic vascular disease)

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Senior

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/12/2001

**Date of final enrolment**

30/11/2003

## Locations

**Countries of recruitment**

United Kingdom

Scotland

**Study participating centre**

Academic Section of Geriatric Medicine

Glasgow

United Kingdom

G4 0SF

# Sponsor information

## Organisation

The Health Foundation (UK)

## ROR

<https://ror.org/02bzj4420>

# Funder(s)

## Funder type

Charity

## Funder Name

The Health Foundation (UK)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/12/2005		Yes	No